Sugi Predict

Sugi Predict / Targets / MAP4K5

MAP4K5

Mitogen-activated protein kinase kinase kinase kinase 5 · Q9Y4K4 · MAP4K5 on Sugi Atlas →

72,636 patent compounds predicted against MAP4K5, 55,316 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL234334 SCHEMBL234334 1.00 5/20
SCHEMBL90887 SCHEMBL90887 0.49 4/20
SCHEMBL90935 SCHEMBL90935 0.49 4/20
Linifanib Linifanib (SCHEMBL93804) 1.00 3/20
SCHEMBL65790 SCHEMBL65790 0.52 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL58421) 0.52 3/20
Plx-4720 Plx-4720 (SCHEMBL133733) 1.00 2/20
Axitinib Axitinib (SCHEMBL172918) 1.00 2/20
Sb-220025 Sb-220025 (SCHEMBL173441) 1.00 2/20
SCHEMBL173595 SCHEMBL173595 1.00 2/20
SCHEMBL173596 SCHEMBL173596 1.00 2/20
SCHEMBL298198 SCHEMBL298198 0.88 2/20
SCHEMBL293053 SCHEMBL293053 0.88 2/20
SCHEMBL293377 SCHEMBL293377 0.83 2/20
SCHEMBL294160 SCHEMBL294160 0.82 2/20
SCHEMBL294126 SCHEMBL294126 0.81 2/20
SCHEMBL297768 SCHEMBL297768 0.80 2/20
SCHEMBL233874 SCHEMBL233874 0.79 2/20
SCHEMBL292477 SCHEMBL292477 0.79 2/20
SCHEMBL293288 SCHEMBL293288 0.79 2/20

Clinical trials — most relevant to MAP4K5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Biomarker Analysis of Gastrointestinal Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAP4K5 binder may also engage these)

ProteinNameSimilarity
Q8BPM2 — 1.000 Q8BPM2 →
Q99JP0 — 1.000 Q99JP0 →
MAP4K3 Mitogen-activated protein kinase kinase kinase kinase 3 1.000 landscape →
Q924I2 — 1.000 Q924I2 →
Q8QFR2 — 0.987 Q8QFR2 →
O35099 — 0.986 O35099 →
A7MBL8 — 0.985 A7MBL8 →
P62205 — 0.985 P62205 →
Q8BWW9 — 0.984 Q8BWW9 →
Q9BXB4 — 0.983 Q9BXB4 →
E9Q4Z2 — 0.983 E9Q4Z2 →
PKN2 Serine/threonine-protein kinase N2 0.983 landscape →
Q07139 — 0.983 Q07139 →
MAP3K5 Mitogen-activated protein kinase kinase kinase 5 0.983 landscape →
Q9H8V3 — 0.982 Q9H8V3 →
CHAF1B Chromatin assembly factor 1 subunit B 0.982 landscape →
A4IID4 — 0.982 A4IID4 →
P28028 — 0.982 P28028 →
MAP3K15 Mitogen-activated protein kinase kinase kinase 15 0.982 landscape →
Q5DQR4 — 0.981 Q5DQR4 →
PI4KB Phosphatidylinositol 4-kinase beta 0.981 landscape →
O08874 — 0.981 O08874 →
Q8CI95 — 0.981 Q8CI95 →
P34908 — 0.981 P34908 →
PLCB1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 0.981 landscape →
Q04982 — 0.981 Q04982 →
Q5SQE2 — 0.980 Q5SQE2 →
P39447 — 0.980 P39447 →
Q641K1 — 0.980 Q641K1 →
Q60HG1 — 0.980 Q60HG1 →